TScan Therapeutics (TCRX) Earnings Date & Reports

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TCRX is expected to report earnings to rise 7.32% to -23 cents per share on August 19

TScan Therapeutics TCRX Stock Earnings Reports

Q2'26

Est.

$-0.24

Q1'26

Missed

by $0.04

Q4'25

Beat

by $0.09

Q3'25

Beat

by $0.06

Q2'25

Beat

by $0.05

The last earnings report on May 07 showed earnings per share of -21 cents, missing the estimate of -18 cents. With 323.14K shares outstanding, the current market capitalization sits at 56.90M.

View a ticker or compare two or three

Compare

TCRX

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for TCRX